sequencing-based diagnostics
Adaptive Bio Narrows 2022 Revenue Guidance, Outlines Financial Expectations
Releasing Q3 results, the Seattle-based immune system biotechnologies firm set its new full-year revenue guidance to the range of $185 million to $190 million.
Adaptive Biotechnologies Inks Partnership to Integrate MRD Assay With Epic's EMR System
After the expected integration in 2023, providers can order Adaptive’s ClonoSeq assay and review the results using the Epic electronic medical record system.
Adaptive Biotechnologies Halts T-Detect Commercialization, Reports 13 Percent Q2 Revenue Growth
Premium
The company realized it is costly to develop single-disease T-Detect assays and is deferring commercialization until a clear path to reimbursement is proven.
Although it has seemingly tried to do everything, everywhere, all at once with its immune sequencing technology, Adaptive has sharpened its focus.
The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.